Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Global IPO Fund (IPOSX)

Net Asset Value
1 Day
Overall Morningstar Rating
Mid-cap growth
Style or Category
No Load
Sales Expenses
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. The fund pursues its objective by investing, under normal circumstances, at least 80% of its net assets, plus any borrowings for investment purposes, in a diversified portfolio of the common stocks, American Depositary Receipts ("ADRs"), real estate investment trusts ("REITS") and master limited partnerships ("MLPs ") (together "securities "), without regard to their market capitalization, of newly listed initial public offerings of domestic and foreign companies ("IPOs") that trade on a U.S. exchange.


1 month-10.22% 3 years+15.21%
3 months-6.66% 5 years+9.70%
1 year-1.66% Since inception+2.10%
Data through --

Peer Comparisonvs. Mid-cap growth

Performance 5-yr return+9.70%+16.81%
Expense ratio2.84%1.31%
Risk 5 year sharpe ratio0.681.07
Net assets$9.7M$1.4B
Average market cap$8.7B$9.8B
Average P/E25.725.2
Portfolio turnover198%198%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyRenaissance Capital
Fund manager & tenureLinda Killian / 17 Years
Minimal initial investment$5,000.00
Minimum IRA investment$2,500.00


U.S. stock93.43%
International stock5.79%
Fixed income0.79%
Top 5 Sectors
Portfolio weighting
Consumer service 20.23%
Hardware 16.89%
Business service 15.36%
Energy 9.38%
Industrial materials 9.29%
Top 10 Holdings
Portfolio weighting
PANW Palo Alto Networks Inc7.56%
FB Facebook7.23%
DPLO Diplomat Pharmacy Inc6.44%
WWAV WhiteWave Foods Co5.28%
EVHC Envision Healthcare Holdings Inc4.76%
TWTR Twitter4.67%
BABA Alibaba Group Holding Ltd4.57%
Q Quintiles Transnational Holdings Inc4.51%
VOYA Voya Financial Inc4.46%
JUNO Juno Therapeutics Inc4.40%

Partner Offers